Pricing Log in Create free account
Friday 6 November 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

SYRE Healthcare Biotechnology

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.

EPS
−624.8%
Free cash flow
−108.8%

Quarter to September 2026, against a year earlier

103.34 6.75 +6.99%
Market cap
$9.2B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
3/9
Altman Z
−3.82
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Spyre Therapeutics, Inc. 8-K filed Jun 15, 2026

Period ended Jun 15, 2026 · Filed · accepted 8:01 AM ET · Document on sec.gov · Filing index

7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov